Peritonitis Prevention & Management: ISPD 2022 Evidence-Based Protocols

ISPD 2022 Diagnostic Framework

Clinical presentation: abdominal pain (most common), cloudy effluent, fever (variable — may be absent). Diagnosis requires 2 of 3 criteria: (1) compatible clinical features, (2) effluent WBC >100/µL with >50% polymorphonuclear cells (after ≥2-hour dwell), (3) positive effluent culture.

Effluent sampling: use the FIRST cloudy bag; collect WBC count, Gram stain, culture (both aerobic and anaerobic bottles). Culture-negative rate should be <15% — high rates indicate technique issues (bedside inoculation into blood culture bottles reduces this).

Treatment timing: initiate empiric therapy immediately after sampling (do not wait for culture) — per ISPD, cover both gram-positive and gram-negative organisms in all cases due to resistance patterns.

Empiric & Directed Therapy

Empiric intraperitoneal: gram-positive coverage — vancomycin (15-30 mg/kg IP every 5-7 days) OR first-generation cephalosporin (cefazolin 500mg/L IP); gram-negative — ceftazidime (500mg/L IP) OR aminoglycoside (gentamicin 0.6mg/kg IP daily). In facilities with high MRSA: prefer vancomycin.

Directed therapy at 48-72 hours by culture and sensitivities. Duration: S. epidermidis — 2 weeks; S. aureus and others — 3 weeks; Pseudomonas — 3 weeks with double coverage; fungal — catheter removal + oral/IV antifungals.

Response monitoring: effluent WBC at 48-72 hours (should fall); clinical improvement (pain, clarity). Refractory peritonitis: no improvement by day 5 → catheter removal and transfer to HD with delayed catheter re-insertion (2-4 weeks).

Prevention Bundles

Training: structured initial training (1-2 weeks), competency assessment, re-training at 6 months and after peritonitis episodes (ISPD recommendation). Use checklists and teach-back methodology.

Connectology: double-bag (Y-set) systems mandatory — randomized trials (CANUSA-era) show ~50% peritonitis reduction vs spiked systems. UV Flash or equivalent disinfection devices for connection.

Exit site care: chlorhexidine or povidone-iodine cleansing at each exchange, no occlusive dressings, prophylactic mupirocin at the exit site (reduces S. aureus peritonitis by ~60% — randomized evidence), and routine exit site scoring (ISPD exit site classification).

Environmental: monthly effluent culture surveillance, water/sanitation audits, and family training for home exchanges. Programs tracking these metrics (ZuvFlo PD module) achieve <0.4 rates.

Outcome Benchmarking

Core metrics per ISPD: peritonitis rate (target <0.4 episodes/patient-year, i.e., 1 episode per 30 patient-months), culture-negative rate (<15%), S. aureus rate (zero target), enteric organism rate, and technique survival (PD continuation at 12 months).

Complication rates: catheter removal due to peritonitis, hospitalization rate, and peritonitis-associated mortality (<5% of episodes) should be tracked quarterly.

Data infrastructure: PD programs should maintain a peritonitis registry (episode log, organism, sensitivity, treatment, outcome) — ZuvFlo's PD module auto-documents episodes with outcomes, enabling quarterly benchmarking and early detection of resistance patterns.